| Expression pattern: |
UP |
| Associated gene: |
SLC7A11 |
| Associated microRNA: |
miR-513a-5p |
| Biological function: |
promotes proliferation, invasion, migration/metastatic capacity and sorafenib resistance; inhibits ferroptosis |
| Molecular mechanism: |
circTTC13 acts as a cytoplasmic miRNA sponge for miR-513a-5p, relieving repression of SLC7A11 and thereby suppressing ferroptosis and promoting sorafenib resistance. |
| Biological pathway or process: |
ferroptosis (inhibits); proliferation (promotes); migration (promotes); invasion (promotes); drug resistance (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; Clinical Sample Validation; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; FISH / smFISH; Luciferase Reporter Assay; Transfection; Colony Formation Assay; Wound Healing Assay; Transwell Assay; MTT; IF (Immunofluorescence); Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circTTC13 expression is associated with advanced pathological grade and tumor stage and poorer overall survival in HCC. |
| Description: |
circTTC13 (hsa_circ_0000195), derived from TTC13, is up-regulated in HCC and mainly localized in the cytoplasm. It promotes HCC malignant behaviors and sorafenib resistance by inhibiting ferroptosis via sponging miR-513a-5p, thereby upregulating SLC7A11. |
| Confidence score: |
0.8567 |